Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients

Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2015-05, Vol.6 (15), p.13579-13590
Main Authors: Mock, Andreas, Warta, Rolf, Geisenberger, Christoph, Bischoff, Ralf, Schulte, Alexander, Lamszus, Katrin, Stadler, Volker, Felgenhauer, Thomas, Schichor, Christian, Schwartz, Christoph, Matschke, Jakob, Jungk, Christine, Ahmadi, Rezvan, Sahm, Felix, Capper, David, Glass, Rainer, Tonn, Jörg-Christian, Westphal, Manfred, von Deimling, Andreas, Unterberg, Andreas, Bermejo, Justo Lorenzo, Herold-Mende, Christel
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Amino Acid Sequence
Autoantibodies - blood
Brain Neoplasms - blood
Brain Neoplasms - immunology
Brain Neoplasms - pathology
Cohort Studies
Female
Glioblastoma - blood
Glioblastoma - immunology
Glioblastoma - pathology
Humans
Male
Middle Aged
Oligopeptides - chemistry
Prognosis
Protein Array Analysis - methods
Research Paper
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liquid biopsies come of age offering unexploited potential to monitor and react to tumor evolution. We developed a cost-effective assay to non-invasively determine the immune status of glioblastoma (GBM) patients. Employing newly developed printed peptide microarrays we assessed the B-cell response against tumor-associated antigens (TAAs) in 214 patients. Firstly, sera of long-term (36+ months, LTS, n=10) and short-term (6-10 months, STS, n=14) surviving patients were screened for prognostic antibodies against 1745 13-mer peptides covering known TAAs (TNC, EGFR, GLEA2, PHF3, FABP5, MAGEA3). Next, survival associations were investigated in two retrospective independent multicenter validation sets (n=61, n=129, all IDH1-wildtype). Reliability of measurements was tested using a second array technology (spotted arrays). LTS/STS screening analyses identified 106 differential antibody responses. Evaluating the Top30 peptides in validation set 1 revealed three prognostic peptides. Prediction of TNC peptide VCEDGFTGPDCAE was confirmed in a second set (p=0.043, HR=0.66 [0.44-0.99]) and was unrelated to TNC protein expression. Median signals of printed arrays correlated with pre-synthesized spotted microarrays (p
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.3791